As of April 20, Shenandoah Oncology will reopen our clinic after a temporary closure. During the time of our closure, our facilities were extensively cleaned and sanitized. Additionally, we have completed a comprehensive evaluation and response coordinated with the Virginia Department of Health and have concluded that it is safe to resume treatment in our clinic. The wellbeing of our patients continues to be our top priority. We are instating additional preventive measures to ensure a safe care environment, including:

  • Enhanced screening of anyone entering the facility.
  • Requirement of anyone entering the building to wear a face covering. We will provide procedure masks to patients.
  • The operational flow in our building has been modified to allow maximize spacing between individuals in our facility.

We know how difficult and stressful this time is for patients and their families. Our care team will continue to evaluate the most appropriate way to provide continued treatment for each patient during the pandemic, whether in person at our office or by telemedicine. We’re here for you! Always.

Clinical Trials

Research News

Meta-Analysis Finds Benefits of Adjuvant Bisphosphonates for Postmenopausal Breast Cancer

September 8th, 2015

Bisphosphonates can reduce the rate of breast cancer recurrence in bone, according to a meta-analysis of randomized trials of bisphosphonates as adjuvant therapy for women with early-stage breast cancer.
Read More

Palbociclib Improves Survival in Women with Hormone Receptor-Positive Metastatic Breast Cancer

July 23rd, 2015

An interim analysis of the PALOMA3 trial shows that palbociclib plus fulvestrant extends the progression-free survival of some women with hormone receptor-positive metastatic breast cancer.
Read More

Pembrolizumab Improves Progression-Free Survival in Patients with Ipilimumab-Resistant Melanoma

July 19th, 2015

Results from the KEYNOTE-002 clinical trial show that pembrolizumab improves progression-free survival in patients with ipilimumab-resistant melanoma.
Read More

Nivolumab-Based Treatments Delay Progression of Advanced Melanoma

June 25th, 2015

In an international, double-blind, randomized phase III trial, the combination of nivolumab and ipilimumab improved progression-free survival compared with ipilimumab alone for patients with advanced melanoma.
Read More

Pembrolizumab Improves Overall Survival in Patients with Advanced Melanoma

May 25th, 2015

In a randomized phase III study, pembrolizumab (Keytruda®) improved survival in patients with advanced melanoma compared with Ipilimumab (Yervoy®).
Read More

Gardasil 9 Vaccine Protects against Additional HPV Types

March 1st, 2015

In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.
Read More

Gardasil 9 Vaccine Protects against Additional HPV Types

March 1st, 2015

In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.
Read More

Gardasil 9 Vaccine Protects against Additional HPV Types

March 1st, 2015

In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine high-risk HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.
Read More

Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma

January 8th, 2015

Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
Read More

Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma

January 8th, 2015

Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.
Read More

 1 2 3 >  Last ›
Learn More